Epstein Secrets

t has to be repeated over time. Looming on the horizon is the promising CTC circulatory tumor cell microfluidic chip test, a blood test developed at Massachusetts General that can isolate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

f Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed

t has to be repeated over time. Looming on the horizon is the promising CTC circulatory tumor cell microfluidic chip test, a blood test developed at Massachusetts General that can isolate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

f Ile. Bert Vogelstein, the lYinzetor of the Ludwig Center for Cancer Genetics and 'Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed

t has to be repeated over time. Looming on the horizon is the promising LTC circulatory tumor cell microfluidic chip lest, a blood test developed at Massachusetts General that can Slate and identify cancer mutations at any given time. To date, the test has identified more than 1,200 cancer-causing genetic mutations,

on of Dr. Ben Vogelstein. the Director of the Ludwig Ccntcr for Cancer Genetics and Therapeutics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. Dr. Vogelstein was studying resistance to a colon cancer inhibitor called panitumumab. Enlisting Dr. Nowak's help. Vogelstein and the PED designed